AstraZeneca says data shows Farxiga reduces risks in heart failure patients
AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga reduced the risk of the primary composite outcome of worsening heart failure, or HF, defined as hospitalization or an urgent visit, or death from cardiovascular, or CV, causes versus placebo, when added to standard of care. DAPA-HF is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of HF in patients with reduced ejection fraction, with and without type 2 diabetes, or T2D. The new analyses showed the consistency of these results across patient subgroups with and without T2D, an early onset of effects, and improvement in patient-reported outcomes of HF-related health status. These data were presented at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. Elisabeth Bjork, senior VP, Head of Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, said: "Heart failure affects approximately 64M people around the world and about half of those patients will die within five years of diagnosis. These new analyses from the DAPA-HF trial reinforce the science behind FARXIGA as clinically significant across heart failure patient populations and suggest the potential to improve the current standard of care for millions of these patients."